**Introduction:** A case of psoriatic arthritis complicated by chronic hepatitis C infection, complex orthopaedic procedures, severe psoriasis, previous tuberculosis infection, anterior uveitis as well as a difficult social situation. This case highlights the need for establishing good communication and close cooperation between specialties and how advancing medical treatment allowed the eventual successful treatment of this patient.

**Case description:** We present a case of a 58 year old gentleman with psoriasis, who is known to Hepatology due to cirrhosis of the liver, secondary to alcohol excess and hepatitis C. He was treated with Interferon in 2008. Due to an exacerbation of his skin and joints he stopped Interferon before the full course was completed and therefore the treatment was unsuccessful. He was referred to Rheumatology and Dermatology. His psoriasis was the overwhelming issue at this time with destructive nail dystrophy, vesicular eruptions of palms and soles, and flexural and scalp psoriasis. He was commenced on Ciclosporin but later stopped due to nephrotoxic side effects. Following review by a rheumatologist he was diagnosed with psoriatic arthritis with dactylitis. At this point Sulfasalazine was considered as a treatment option, but for an unknown reason this was never implemented and he was maintained on low dose prednisolone. For the next 2 years he continued to be followed up by Hepatology but there were no further options for Hepatitis C treatment at this time. His liver function remained stable. He was also seen by Rheumatology and Dermatology specialists but due to significant liver disease, his treatment options were limited. His psoriasis the treatment remained topical. No DMARDs were started. During this period he had a number of operations including amputation of left little and middle finger and fusion of MTPJ. These were complicated by exacerbation of his psoriasis, wound infection and breakdown, and the need for revision surgery on his MTP joints. There were concerns regarding his social situation at various times with the involvement of occupational therapy for more appropriate housing. At the end of 2014 he was seen again in Rheumatology (having been lost to follow up) and at this point it was noted that his psoriatic arthritis and psoriasis were severe causing significant discomfort and limitation in activities of daily living. Communication between Hepatology and Dermatology was reinstated, however there continued to be limited options for treatment due to his hepatitis and liver dysfunction. Treatment options discussed included Methotrexate (contraindicated), Sulfasalazine (caution) and biologics (concerns regarding sepsis due to orthopaedic complications and hepatitis). A considerable complication of his orthopaedic procedures and poor wound healing was osteomyelitis in his right 3rd metatarsal and he was started on an 8 week course of antibiotics after MRI confirmation and a wound swab growing Staph. aureus. Forefoot amputation had been considered but thought too risky due to recurrent infections and wound breakdown. However, continuing presence of osteomyelitis, despite antibiotics, resulted in an amputation. He was then started on Sulfasalazine but developed a severe rash so this was promptly stopped. A breakthrough came in summer 2015 when he became a candidate for interferon free drug therapies for hepatitis C. After a 12 week course he was successfully treated and the hepatologists were happy to consider him for biologic therapy. He had a short course of Apremilast but this was ineffective and therefore a joint decision between Rheumatology, Dermatology and Hepatology meant the next treatment of choice was Etanercept. During his education consultation the patient mentioned he had tuberculosis as a child. A quantiferon test returned an indeterminate result and after discussion with Respiratory physician he was commenced on 6 months of Isoniazid and Pyridoxine. It was suggested that after his first month of treatment he could start Etanercept (Benepali). Prior to Etanercept initiation his psoriatic arthritis and psoriasis deteriorated and he was non-specifically unwell. He developed a microcytic anaemia and his CRP was 147. There was a concern about a more sinister cause for these blood results so he was investigated with a CT-TAP, blood cultures and an ultrasound of lymph nodes, but no infection or malignancy was found. Isoniazid and Pyridoxine were stopped after 3 months due to concerns that Isoniazid may have contributed to deterioration. His general deterioration and increased inflammatory markers were contributed to active psoriatic arthritis and psoriasis and he was commenced on Etanercept. A review in combined Dermatology and Rheumatology clinic in April 2017, three months after starting treatment, noted a good improvement in his skin and joints associated with an improvement in his CRP (which had decreased to 14) and an improvement in haemoglobin (helped by iron supplementation). There was no active disease clinically in his hands and none on the most recent ultrasound of his feet and shoulders. Currently his blood count is being monitored as his haemoglobin and platelets have decreased. It is presumed that this is due to Etanercept and further modifications in biologic treatment may be necessary.

**Discussion:** This was a difficult case to manage due to multiple, complex co-morbidities giving us limited treatment options. There are case reports describing anti-TNF therapy in the setting of a Hepatitis C infection showing that in the majority of patients this did not worsen the Hepatitis C infection. However, there are limited numbers of cases and there are no controlled studies. Etanercept is the most commonly used biologic in these papers. Etanercept can rarely cause thrombocytopenia which tends to recover after the drug withdrawal and does not necessarily reoccur with different anti-TNF therapy. Although regular blood monitoring is not required with anti-TNF treatments, routine blood cell count shortly after commencement of the therapy would be prudent particularly in patients with multiple co-morbidities and risk factors. Combined clinics are invaluable for management of complex cases and our patient has certainly benefited from the review in the combined clinics with the Dermatology team. A case conference with Hepatology and Foot and Ankle team would have been beneficial but these sessions are challenging to organise due to time constraints and clashing timetables. Limitations and delay in communication between specialties did contribute to delay in treatment and inadequate management.

Key learning points: Communication is essential in complex cases like this. When possible, combined clinics with specialties such as Dermatology and Foot and Ankle team should be established. Continuity of care should be preserved and overall care coordinated by one consultant who is familiar with the case. The role of patient education and their involvement in decision making is key, particularly in those whose treatment and outcomes are uncertain. It was clear from the letters this gentleman was fully aware of the risks and benefits of all his treatments, medical and surgical. In addition to this, the patient education appointment and counselling for Etanercept brought to light the previous TB infection which may have otherwise been overlooked. Routine blood cell count should be considered after commencement of Etanercept in view of rare, but potentially severe, adverse haematological events.
